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a b s t r a c t
Using mixed-methods, we investigated the CDF in the South West of England (3193 cancer patients
treated through the CDF, April 1st 2011–March 31st 2013) for evidence of: (1) equitable access across
socioeconomic groups, age groups, sex, and Cancer Network; (2) time-to-treatment by socioeconomic
group; and (3) the perception of the CDF as fair, using semi-structured interviews with oncology consul-
tants.
There was no evidence of inequitable access to anti-cancer therapy for those in more deprived areas.
For all cancer types, therewas a lower proportion ofwomen in the CDF cohort than in the Cancer Registry
reference population (e.g., melanoma, CDF 36.8% female, reference population 48.7%; difference 11.9%,
95% CI 3.1–20.7%). Therewas a lower proportion of older patients in the CDF comparedwith the reference
population (e.g., colorectal cancer, CDF 6.9%≥80 years, reference population 30.1%; difference 23.2%, 95%
CI 20.2–26.2%). Interviewedoncologists felt differences in performance status, not age, inﬂuenced referral
to the CDF, with neither deprivation, nor gender contributing.
Our study suggests that the CDF has differential access by age and sex, but not by deprivation. The
absence of high quality CDF data represents a missed opportunity to fully evaluate equity of access and
the real-world costs and outcomes of novel anti-cancer drugs.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
In 2011, the UK government introduced a £200 million Cancer
Drugs Fund (CDF) to improve access to cancer drugs in England [1].
The CDF allowed access to: (a) drugswhichwere not recommended
by the National Institute for Health and Care Excellence (NICE)
because of poor or unproven cost-effectiveness; (b) drugs which
had not yet been appraised by NICE; and (c) drugs used outside
their marketing authorisation (off-label). In 2013, funding for the
CDF was increased to £280 million annually and in 2014, a further
budget increase (to £340 million) was coupled with the introduc-
tion of cost-effectiveness as a criteria for drug availability on the
CDF. This was primarily due to a CDF overspend (£30.5 million in
2014) [2], but also reﬂects the rising number of high-cost cancer
drugs, increasing cancer incidence [3], and the absence of a plan to
disinvest from existing drugs to make way for new therapies. The
opportunity cost of the CDF has been the subject of intense debate,
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for example, about whether the money could be better spent on
other cancer treatment modalities and/or other diseases [4].
Inequity of access to anti-cancer therapy in the UK, prior to the
CDF, has been demonstrated by: age [5,6]; deprivation [7–9]; place
of residence [10]; hospital involvement with clinical trials [11],
and hospital processes for facilitating best patient care (such as
Multi-Disciplinary Teammeetings) [12]. The intent of the CDF is to
provide all patients with better access to “cancer drugs their doc-
tors think will help them” [1]. However, there is no peer-reviewed
evidence on whether the CDF has reduced or exacerbated inequal-
ities in access to anti-cancer therapy. Using mixed-methods, we
assessed the strengths and weaknesses of the CDF for research
and investigated (1) whether access to the CDF during 2011–2013
was distributed equally across socioeconomic groups, age groups,
sex, and Cancer Network; (2) whether time to treatment on the
CDF varied by socioeconomic group; and (3) whether the CDF was
perceived by oncologists as being fair.
http://dx.doi.org/10.1016/j.jcpo.2015.06.003
2213-5383/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
0/).
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2. Methods
2.1. CDF cohort
Anonymised patient-level CDF data for the period April 1st
2011–31st March 2013 for the south west (SW) region of England
were obtained from NHS England South including age, sex, can-
cer type, cancer drug, general practitioner (GP) postcode, referring
hospital trust, CancerNetwork, CDF panel decision, treatment start,
and end date and date of death. Cancer Networks (CN) were con-
federations of health organisations responsible for delivering the
National Cancer Plan [13] in designated areas (now Strategic Clin-
ical Networks (2013)) [14]. Data were not available after March
31st 2013 because regional CDF arrangements were transferred
to a National Cohort List (a centrally agreed list of drugs avail-
able across England through theCDF).Out-of-region applications to
the CDF (i.e., applications received in error and referred to another
regional CDF) were excluded from the analysis, as were applica-
tions during the interim CDF period (October 1st 2010–March 31st
2011). Applications to the CDF which were not approved (3.0%)
were not included in the analysis. Individuals who applied to the
CDF more than once were identiﬁed by initials, GP postcode, diag-
nosis and age, and only the ﬁrst application (93.8% of applications)
was included in the analysis. Our primary analysis included SW
patients resident in all six CNs (Avon Somerset and Wiltshire Can-
cer Services (ASWCS), Dorset, Peninsula, 3 Counties, Central South
Coast, andThamesValley)whichwerepartiallyorwholly contained
within the SW region. GP postcode data for all CDF participants
(individual patient postcode data were not provided) were linked
to lower super-output areas (LSOA) to obtain National Index of
Multiple Deprivation (IMD 2010) quintiles [15]. Participants were
grouped into nine diagnosis categories based on the cancer name
recorded on the CDF application. International Classiﬁcation of Dis-
eases (ICD-10) diagnosis codes were very poorly recorded (49.0%
missing or coded ‘N/A’) in the CDF. The diagnosis categories were:
colorectal; prostate; breast; malignant melanoma; lung; gynae-
cological; upper gastro-intestinal; haematological; and other rare
cancers. ‘Gynaecological cancer’ included uterine, ovarian and cer-
vical; upper GI cancer included gastric, hepatic, pancreatic, and
duodenal; and haematological cancer was made up of 84 differ-
ent categories, including pre-cancerous conditions ofmyeloﬁbrosis
and amyloid. Other rare cancers were categorised based on being
a member of the rare cancers list [16] and not being included in
other named categories. Ethical approval was granted by the SW
REC (REC reference 13/SW/0007 January 2013).
2.2. Cancer registry ‘reference’
We used cancer registry (CR) data to identify a comparative
group of patients with advanced cancer in the SW regionwhowere
potentially eligible for CDF drugs (the ‘reference population’). The
CR data, which includes information on cancer type, cancer stage,
age, sex, and CN, were obtained from the public health England
(PHE) Knowledge and Intelligence Team (SW). In our primary anal-
ysis of seven of the nine cancer types, CR patients were included in
the reference population if they had the same cancer type,matched
to theappropriate ICD-10code, (Supplementarymaterial) andwere
‘advanced’ stage (IV). We selected only advanced stage tumors
as this represents the subgroup of cancer patients most likely to
be eligible for drugs prescribed on the CDF. In sensitivity analy-
sis we expanded our inclusion criteria to include all stages. For
malignant melanoma, where Tumour-Node-Metastases, based on
Breslowstaging,maybeusedmore commonly clinically, andwhere
stage IV cancers in the CR number less than those treated in the
CDF, the reference population in the primary analysis included
‘all’ melanomas. For haematological cancers, where there is little
stage 0–IV information in the CR, ‘all’ haematological cancers were
included in the reference population in the primary analysis. CR
patients’ postcodes were linked to IMD quintiles via LSOA.
2.3. Statistical analysis
2.3.1. Equity of access
Of 3530 CDF applications, 8 were out-of-region residents, 234
repeat applications for the same patient and 95 were not autho-
rised by the CDF panel and were excluded from analysis, leaving
3193 (Fig. 1). Of these, 367 (11.5%) had missing or incomplete GP
postcodes and could not be assigned an IMD designation. Other
patient characteristics were missing in ≤2% of CDF applications.
Chi-Squared, Ordinal Chi-squared, and Fisher’s Exact tests were
used to compare demographic characteristics of those treated on
the CDF with the reference population.
2.3.2. Time-to-treatment
Time to receipt of treatment was calculated from the date of
CDF panel authorisation to the date of treatment. Treatment start
date was missing or incomplete for 1330 (41.7%) patients. Due to
the large proportion ofmissing data, data were explored and found
to be ‘missing at random’ for all observed variables apart from CN.
A further 348 patients were excluded due to dates of authorisa-
tion occurring after treatment had started. Cancer typeswith fewer
than 100 subjects were excluded from the regression analysis. The
ﬁnal model excluded missing data in IMD (n=222) age (n=22),
and sex (n=5) resulting in a ﬁnal time-to-treatment analysis of
899 patients. Cox regression was used to calculate multivariable
adjusted hazard ratios for time-to-treatment, where a hazard ratio
>1 indicates more prompt treatment. Potential confounders were
identiﬁed a priori and assessed for inclusion using likelihood ratio
tests to develop the ﬁnal model (adjusted for age, sex, cancer type,
CN) for the impact of deprivation on time-to-treatment. All statis-
tical analyses were performed with Stata 13.1 (StataCorp).
2.4. Sensitivity analysis
In the absence of a unique patient identiﬁer linking the CR to
the CDF, or complete diagnostic (ICD-10) coding in the CDF, two
sensitivity analyses were conducted to assess assumptions used in
selecting the ‘reference population’ in the CR. Firstly, we included
‘all stage’ cancers of the same cancer type in the reference popu-
lation to test the assumption that ‘all’ stages better reﬂected the
population who were eligible to apply for the CDF than advanced
CR cancers in the primary analysis. Secondly, the study population
was restricted to those treated in the three CNswhose entire popu-
lationwas eligible for the SWCDF (ASWCS, Dorset, Peninsula). This
addresses the possibility that equity of access to the SW CDF was
being distorted by including CNs where some residents get care
through other regional CDFs.
2.5. Interview study
As part of a wider qualitative study, all colorectal and urological
oncology consultants in four hospitals in the SW region were iden-
tiﬁed through hospital switchboards and websites and invited to
take part in semi-structured interviews. Thirteen email and postal
invitations were distributed and ten interviews were conducted
between April 1st and December 31st 2013. Interview topic guides
wereused and includedquestions about the criteria that inﬂuenced
the oncologists’ decision to refer a patient to the CDF, experiences
of the CDF and its perceived impact on patients. Analysis used
the technique of constant comparison to compare transcripts and
elicit key themes [17]. The researchwas conducted iteratively,with
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3,530 applicants to the CDF
Equity of access CDF analysis 
(Table 1) (3,193 analysed)
Excluded: missing IMD (367)
Equity of access IMD analysis 
(Tables 3&4) (2,826 analysed)
Excluded: missing/incomplete treatment start date, 
(1,315) treatment not started (95) or not within 
me scenario (eg panel authorised aer treatment 
start (347))
For ﬁnal model excluded:
missing IMD (222) , missing age(26) missing sex (5)
Excluded: 
cancers with less than 100 subjects (161) 
and those outside three CNs wholly in 
SW (206)
899 included in me to 
treatment analysis (Table 5) 
Applicaons sent erroneously 
for out of region residents 
(8 excluded)
Applicaon not authorised by 
CDF panel for treatment 
(95 excluded)
Repeat applicaons for the same 
individual (234 excluded)
Fig. 1. Cancer Drugs Fund participant ﬂow chart.
the topic guide updated to focus on emergent themes. Recruit-
ment continued until data saturation was reached. For this paper,
interview excerpts were selected to inform interpretation of the
quantitative data.
3. Results
In the 3193 unique patients (Table 1) approved for CDF treat-
ment in the two year cohort period, there were 77 different cancer
drugs prescribed at 31 hospitals. Table 2 displays interviewed par-
ticipant characteristics (n=10).
3.1. Equity of access
3.1.1. Age and sex
There were fewer than expected numbers of patients in the 80
years andover age category in theCDF comparedwith the reference
population, most notably in colorectal cancer patients (6.9% in the
CDF, 30.1% in the reference population, difference =23.2% (95% CI
20.2–26.2)) (Table 3, Supplementary Table 1). In all cancer types
studied, there was a lower proportion of women in the CDF than in
the reference population. The difference was largest for melanoma
(CDF 36.8% female, reference population 48.7%; difference 11.9%
(95% CI 3.1–20.7%)).
Oncology consultant participants universally felt that chrono-
logical age was not a ‘discriminator’ for referral to the CDF but
that older patients may not be referred where their co-morbidities
prevented it.
“I think the age issue is driven by general performance
status. . .it’s a question of whether someone is ﬁt enough for
treatment...people who are elderly will have less access to the
drugs fund and that’s a reﬂection that they have other medical
problems. . .I don’t think we select against patients on the basis
of age” [Dr. A, colorectal oncologist].
3.2. Socioeconomic status
The evidence of an association between socioeconomic status
and inclusion in the CDF was inconsistent between cancer types.
Prostate cancer and melanoma had greater proportions of indi-
viduals in more deprived areas (IMD quintiles 1–2) in the CDF,
compared with the expected proportion based on the reference
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Table 1
Baseline characteristics of the CDF cohort.
Age (years) 0–59 800 (25.1%)
60–69 972 (30.4%)
70–79 963 (30.2%)
≥80 397 (12.4%)
Missing 61 (1.9%)
Diagnosis category Haematological (and amyloid) 808 (25.3%)
Colorectal 650 (20.4%)
Prostate 529 (16.6%)
Breast 389 (12.2%)
Other rare cancers 350 (11.0%)
Upper GI 136 (4.3%)
Skin 129 (4.0%)
Gynaecological 106 (3.3%)
Lung 87 (2.7%)
Unknown 4 (<1%)
Missing 4 (<1%)
Gender Male 1890 (59.2%)
Female 1282 (40.2%)
Missing 21 (<1%)
IMD quintile (2010) 1 (Most deprived) 266 (8.3%)
2 632 (19.8%)
3 758 (23.7%)
4 641 (20.1%)
5 (Least deprived) 529 (16.6%)
Missing 367 (11.5%)
Table 2
Interview participants.
Participant
(n=10)
Speciality Years a
consultant
> or ≤10 years
Sex Employment
setting
Dr. M OncColo ≤ F DGH
Dr. H OncColo ≤ F DGH
Dr. Y OncColo > M DGH
Dr. X OncColo > F DGH
Dr. A OncColo > M TH
Dr. C OncColo > F TH
Dr. D OncUrol > M TH
Dr. B OncUrol ≤ F TH
Dr. I OncUrol ≤ F DGH
Dr. G OncUrol > F DGH
Abbreviations: DGH—district general hospital, TH—teaching hospital, OncoUrol—
oncology consultant specialising in urological disease; OncColo—oncology consul-
tant specialising in colorectal disease.
population: e.g., prostate cancer 31.8% CDF, 25.2% reference popu-
lation, quintile 1&2 ([difference =6.6% (95%CI 1.7–11.5%)]) (Table 3,
Supplementary Table 1).
All but one interviewed oncologist dismissed the idea that
socioeconomic status might inﬂuence referral patterns. One inter-
viewed oncologist felt that a possible exception may be when a
complex explanation of the risks and beneﬁts of a treatment was
required (in this context an off-label drug on the CDF). In this
instance, deprivation may inﬂuence the likelihood of referral if an
alternative treatment could be chosen that required less explana-
tion.
“I suppose the only question about deprivation is would the
patient understand side effects and when to get help, so that
might sway you a little bit [not to refer to the CDF].” [Dr. X,
colorectal oncologist].
3.3. Cancer network
Use of the CDF by different CNs varied by cancer type (Table 4,
Supplementary Table 2). Variation between CNs was most evident
for colorectal and gynaecological cancers. For example, patients
residing in ASWCSmade up a higher proportion of the CDF colorec-
tal cancer cohort (55.0%) than the colorectal reference population
(34.7%), but the opposite trendwas observed for the gynaecological
cancer CDF (22.0%) and reference population (43.2%). There was no
variation in referral to the CDF by CN for breast, upper gastroin-
testinal, melanoma, and other rare cancers.
Three oncologists described a sense that geographic variation
had increased during the regional CDF but decreased following the
introduction of the National Cohort List.
“. . .creating the regional Cancer Drugs Fund. . .reintroduce [d]
the postcode prescribing that we were trying to get rid of by
having NICE. . .it’s a huge waste of money. . .having it in four
places around the country just to create inequality. . .it’s been
made into a central panel which is better. . .but then why not
just make it part of NICE.” [Dr C, colorectal oncologist].
Sensitivity analyses showed no difference in the direction of
trends (Supplementary Tables 3 and 4).
3.4. Time-to-treatment
Time-to-treatment did not vary by IMD quintile or sex (Table 5).
Patients in the Dorset CN had a faster time-to-treatment (hazard
ratio) (HR) 1.25 (95% CI 1.04–1.50, P=0.019, median 9.9 days) com-
pared with ASWCS (reference group 1.0, median time 15.8 days).
4. Discussion
Our study suggests that receiving primary care from a deprived
area has not been associated with worse access to the CDF. The
majority of interviewed participants believed there would be no
Table 3
The Population of the CDF compared with the reference population for the CDF in the CR: Age, sex and socioeconomic status.
Haem CDF (%) Haem CRa (%) CRCCDF (%) CRC CR (%) Prostate CDF (%) Prostate CR (%) Breast CDF (%) Breast CR (%)
Age (years) 0–59 143 (18.2) 513 (18.8) 203 (31.5) 287 (17.9) 21 (4.1) 60 (5.2) 170 (44.6) 160 (29.0)
60–69 219 (27.9) 614 (22.5) 229 (35.4) 372 (23.2) 125 (24.7) 268 (23.4) 115 (30.2) 111 (20.1)
70–79 273 (34.8) 776 (28.5) 171 (26.2) 464 (28.9) 241 (47.5) 418 (36.5) 64 (16.8) 145 (26.3)
≥80 150 (19.1) 823 (30.2) 45 (6.9) 483 (30.1) 120 (23.7) 399 (34.9) 32 (8.4) 136 (24.6)
X2 trend p value <0.001 <0.001 0.027 <0.001
Sex M 508 (63.3) 1544 (56.5) 388 (59.9) 869 (54.1) 529 (100) 1000 (100) 0 (0) 4 (0.7)
F 294 (36.7) 1182 (43.3) 260 (40.1) 737 (45.9) 0 (0) 0 (0) 386 (100) 548 (99.3)
X2 p value 0.001 0.013 – –
IMD (2010)1 (most deprived) 64 (9.2) 174 (6.4) 46 (7.8) 121 (7.5) 48 (10.6) 83 (6.7) 24 (6.9) 37 (6.7)
2 158 (22.8) 480 (17.6) 144 (24.3) 304 (18.9) 96 (21.2) 229 (18.5) 77 (22.0) 120 (21.7)
3 162 (23.4) 758 (27.8) 164 (27.7) 417 (26.0) 131 (28.9) 337 (27.2) 99 (28.5) 139 (25.2)
4 164 (23.7) 815 (30.0) 132 (22.3) 462 (28.8) 114 (25.2) 371 (30.0) 79 (22.7) 159 (28.8)
5 (least deprived) 145 (20.9) 499 (18.3) 107 (18.0) 302 (18.8) 64 (14.1) 218 (17.6) 68 (19.6) 97 (17.6)
X2 trend p value 0.018 0.016 0.001 0.725
Haem: Haematological CRC: Colorectal cancer.
a Denotes where ‘all’ stage of cancers are presented in place of stage IV cancers.
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Table 4
Cancer network in the CDF and in the reference population.
Cancer
network
Haem
CDF (%)
Haem
CRa (%)
CRC
CDF (%)
CRC
CR (%)
Prostate
CDF (%)
Prostate
CR (%)
Breast
CDF (%)
Breast
CR (%)
ASWCSb 249 (37.5) 1015 (43.1) 286 (55.0) 557 (41.4) 184 (38.5) 376 (35.7) 158 (46.5) 189 (40.0)
Dorset 128(19.3) 432 (18.3) 70 (13.5) 243 (18.1) 62 (13.0) 190 (18.1) 64 (18.8) 94 (19.9)
Peninsula 287 (43.2) 909 (38.6) 164 (31.5) 545 (40.5) 232 (48.5) 486 (46.2) 118 (34.7) 189 (40.0)
X2 p value 0.031 <0.001 0.044 0.172
a Denotes where ‘all’ stage of cancers are presented in place of stage IV cancers.
b Avon Somerset and Wiltshire Cancer Network.
Table 5
Timeliness of treatment on the CDF.
Time to treatment
n=899
HR (95% CI) HR
>1: faster time
to treatment
P-value
IMD 2010 National Quintile 1(most) 1.0 –
2 0.96 (0.75–1.24) 0.779
3 0.84 (0.66–1.08) 0.173
4 1.00 (0.78–1.29) 0.983
5 (least) 0.83 (0.63–1.09) 0.178
Test for trend 0.300
Age 0–59 1.0 –
60–69 1.00 (0.83–1.20) 0.986
70–79 0.95 (0.79–1.16) 0.637
≥80 0.95 (0.75–1.20) 0.663
Test for trend 0.569
Gender M 0.94 (0.79–1.11) 0.460
F 1.0 –
Cancer network ASWCS 1.0 –
Dorset 1.25 (1.04–1.50) 0.019
Peninsula 1.03 (0.88–1.20) 0.722
Cancer type Haematological 1.0 –
Colorectal 1.00 (0.82–1.22) 0.984
Prostate 0.98 (0.80–1.20) 0.857
Breast 1.05 (0.81–1.36) 0.702
Other rare 1.34 (1.06–1.71) 0.062
association between CDF referral and patient deprivation. Prostate
and melanoma cancer patients, who received their primary care in
more deprived areas, were marginally more likely to be treated
on the CDF. The willingness of clinicians to provide the most
innovative treatment for those presenting with advanced disease
(where advanced presentation ismore likely in themore deprived)
[18], combined with the tolerability of some newer cancer agents
(e.g., Abiraterone) may explain this unexpected ﬁnding in the CDF.
Prior to the CDF, increasing deprivation had been associated with
reduced access to anti-cancer therapy in the literature [7–9].
Whether the preponderance of younger patients on the CDF is a
consequence of better performance status (ﬁtness for anti-cancer
therapy), younger patients’ preference for more aggressive ther-
apy or clinician preconceptions and inequities of referral, cannot
be determined without information on patients’ performance sta-
tus. Interviewed oncologists felt poor performance status, not older
age was the key barrier for referral to the CDF. The literature cor-
roborates older age as a barrier to anti-cancer therapy, even after
adjustment for performance status [5,19].
The differential in CDF referral by gender is conceivably due
to poorer performance status at presentation among females. The
literature on equity of access to anti-cancer therapy by gender is
limited, but a Canadian study found greater access to anti-cancer
therapy for men [20]. Potential explanations could include, prefer-
ence sensitive care [21], where gender treatment choices exclude
systemic anti-cancer therapy or inadequate access due to com-
peting family commitments. No literature was identiﬁed which
corroborated these hypotheses.
Differences between CNs demonstrates a continuing ‘post-
code’ lottery, which is in keeping with the clinician participant’s
wider concerns about geographical inequalities resulting from the
regional CDF. There is also substantial evidence for variable access
to anti-cancer therapies by healthcare jurisdiction prior to the CDF
in the literature [22–25].
4.1. Strengths and limitations
Comparing the CDF population with a reference population
gives conservative results because the numerator (CDF partici-
pants), is also included within the denominator (CR reference
population), thereby attenuating differences between the two
groups. Deprivation in the CRdatawas estimated from the patient’s
residential postcodewhereas in the CDF, GP postcodewas used as a
proxy. As GP populations residewithin local boundary areas, we do
not believe this will have an important inﬂuence on our ﬁndings.
Imperfect matching between CDF and reference populations for
‘advanced’ cancer stagemay introduce selectionbias if CDFpatients
have more advanced disease than reference populations.
4.2. Implications
Our analysis of equity of access to the CDF is restricted by the
absence of key clinical variables (e.g., performance status) and
incomplete data, (e.g., >40% in treatment start date) which would
be required to more fully measure equity and assess survival. The
paucity of these prospectively collected data, which also excluded
quality of life, adverse event, and other core outcome data is inde-
fensible, as recognised in the House of Commons Committee of
Public Accounts (2015) [26]. If data quality cannot be improved,
future research should rely on linkage with reliable data sources
(e.g., CR, Hospital Episode Statistics) to overcome some limitations
of existing data, and adjust for co-morbidity as a proxy for perfor-
mance status. Given the huge amounts invested in the CDF, these
data are a missed opportunity for research.
5. Conclusion
Our study foundno increase in inequity of access to these agents
by socioeconomic status. Age and sex differences in access may
reﬂect unmeasured differences in patients’ performance status,
patient preferences, or inequity resulting from clinician pre-
conceptions about ﬁtness for therapy and patient wishes. Data
incompleteness and absent essential variables, such as perfor-
mance status, in the CDF data has made drawing ﬁrm conclusions
challenging. The CDF represents a missed opportunity for research
into the equity of access and real-world costs and outcomes of
anti-cancer therapies.
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